Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. - Wikidata - wikimedia - TriplyDB

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

http://www.wikidata.org/entity/Q39828440

about

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 Immunobiology of hepatocarcinogenesis: Ways to go or almost there?Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature Functional Mechanisms of Treg in the Context of HIV Infection and the Janus Face of Immune Suppression Emerging therapeutic targets in esophageal adenocarcinoma Advances in immunotherapy for melanoma Translating Treg Therapy in Humanized Mice Predictive factors for immunotherapy in melanoma Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors Predictive biomarkers in precision medicine and drug development against lung cancer Pathways and therapeutic targets in melanoma Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions Immunotherapy advances for glioblastoma CTLA-4 blockade in tumor models: an overview of preclinical and translational research Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer Immunotherapy for primary brain tumors: no longer a matter of privilege Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications An updated overview of HPV-associated head and neck carcinomas The blockade of immune checkpoints in cancer immunotherapy Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Recent advances in understanding antitumor immunity The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma Immunotherapy for Gastroesophageal Cancer The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 Targeting immune checkpoints in malignant glioma Immune checkpoint therapy for pancreatic cancer Immune checkpoint blockade: a common denominator approach to cancer therapy Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors Mechanisms of action of therapeutic antibodies for cancer Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production Cancer immunotherapy via dendritic cells PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

P2860

Q24629841-B23F6115-FF8B-419D-A099-FA5DBE0C2D20 Q24634871-9F34D441-6FD8-439B-932F-8211D184638F Q26738293-CC1ADA99-B632-4EF1-B941-43F922F45780 Q26741242-19C62CFB-9AFC-473C-A769-9DB311894A81 Q26744626-343BC3A7-64A1-4F41-90A8-AC8C2616B244 Q26751209-47BF8FE4-947D-48C4-BF1C-86BBFC3DF486 Q26768558-C2FCA28A-27B5-430D-818C-643221985B5F Q26772335-64DF605A-E915-41B0-AD94-3F8160F1FE96 Q26778765-602CCF1C-8E44-42E4-A107-176B7D6B3053 Q26779184-7404E4F1-3800-425C-BC5C-13F5B87C41FF Q26781038-CA549111-F6E2-4C18-B193-E0C789BC906F Q26783783-CFC99E1F-2795-462B-B16B-DD1EED0E93A9 Q26796099-21AD917E-B26E-4387-8C32-1CB288C90C34 Q26799812-AF9BC82B-18C3-4FFF-918E-574E7CFDD9F3 Q26824536-549B856A-FCB7-43B6-B456-1C84AC1C43C3 Q26865736-024DEA8C-641D-4BC3-A14D-C0A8BC535340 Q26865859-413BB23F-BE28-450E-8C28-592ECA26BEBF Q26866513-FB3913BB-CB48-44F6-964C-32EF251CED26 Q26992295-A8060C22-965B-4334-8421-6C5DFAC4796E Q26996829-FB524FDA-7980-4BB4-87B9-AB6FDE7F832A Q27002510-942CE2D9-AC6B-4097-90BA-7462F5F26FE2 Q27008625-375B888F-2005-49D8-AD6D-1CEB5D2999D9 Q27011510-FA2F9F61-8B5F-4AE0-BBB5-82A43472DA45 Q27014019-852DFC53-FAB7-498C-B5D5-CFD7B19FA24E Q27860852-2170E219-D0EC-4B38-A87E-7A40FFB33BAE Q28066199-1DDE00EF-1DDD-4A3E-A06B-6807F7E6B5F0 Q28067217-9E4684B9-AA09-41E6-A658-833B9328E576 Q28069826-CABD62B0-0657-4607-A3AD-952D9027499E Q28069873-AE32EAAD-1E45-473B-A2A5-07594B42E9A4 Q28069924-CA678C87-5C6E-467B-A907-D05D35079CE7 Q28072012-AF98EE35-EBFB-4626-A7B8-923D37E0155E Q28078390-505C05E0-585D-4A5C-B531-1205AFADB638 Q28083981-1380BC92-4B79-453F-B249-9D8043839CBF Q28086999-6898CAD4-6B2C-4BB5-85BF-1B228554554E Q28385366-ACAB09AF-CADC-4A78-A22C-CE9CFB11CA43 Q28550203-89126314-1CEF-4FD9-99F7-07CDED18558A Q28730798-83B6F915-E729-42C0-AEC3-60414D2B856B Q28740530-1FB6EC46-CAFD-4541-BF3F-37B1414DF013 Q29615444-44ACB267-E5C6-4ADC-AA87-D5B6B90EB42F Q29619686-D3BB53B1-3078-4691-A74E-B6DD835D93CA

P2860

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

http://www.wikidata.org/entity/Q39828440

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Blockade of CTLA-4 on both eff ...... ity of anti-CTLA-4 antibodies.

@en

Blockade of CTLA-4 on both eff ...... ity of anti-CTLA-4 antibodies.

@nl

type

label

Blockade of CTLA-4 on both eff ...... ity of anti-CTLA-4 antibodies.

@en

Blockade of CTLA-4 on both eff ...... ity of anti-CTLA-4 antibodies.

@nl

altLabel

Blockade of CTLA-4 on both eff ...... vity of anti-CTLA-4 antibodies

@en

prefLabel

Blockade of CTLA-4 on both eff ...... ity of anti-CTLA-4 antibodies.

@en

Blockade of CTLA-4 on both eff ...... ity of anti-CTLA-4 antibodies.

@nl

P1433

Q39828440-1CAD4C05-B8BE-47C2-94D7-B58FF60411A6

P1476

Q39828440-F2262BDE-B3F5-4036-9559-742A62ED532D

P2093

Q39828440-1288E977-36EC-437A-B10A-4354255A8347

Q39828440-B173D989-92E8-4960-9254-D69126C50A67

Q39828440-BC26413F-AF91-40A4-A558-46B30801E6CD

P2860

Q39828440-1944D5A0-A4E4-46A1-81E5-0592F08D365F

Q39828440-1A04779A-37AB-4416-8FFA-2C8857FA78DB

Q39828440-214D07D0-8EF9-4AF1-93FB-88B0DBA333A4

Q39828440-23DBCD21-CB49-414A-9BC1-45BDF131C3E5

Q39828440-2DF7B152-FD93-4D36-AF37-32CB855F397A

Q39828440-33E10934-15A6-42EA-8087-9AAF71B1453A

Q39828440-35DE7395-BE61-4665-815E-E8270BAB1D90

Q39828440-36102A6D-81A9-41D4-A140-981DE3D77BDD

Q39828440-3A42AA25-559E-4ABF-A349-74E882EFF32F

Q39828440-3D6D0DD9-34A9-46B7-9F24-77546DD728A9

P304

Q39828440-30708A32-2ED1-423F-A856-1F3525C950D0

P31

Q39828440-B1C65790-6CD1-4434-A111-64D695950BE1

P356

Q39828440-769C8787-FE6A-48F9-B79E-88FA97630DF4

P407

Q39828440-16AE0B36-16DE-4326-BE8C-5BFE1297D585

P433

Q39828440-2E39FAFE-8DE7-4E13-B879-430F6288C3AF

P478

Q39828440-3CFA4BF2-65CD-4277-8E39-D64465E65C77

P50

Q39828440-1D6206AC-4770-4162-8CC4-96552098EC98

Q39828440-E4FC3A8D-93BD-4375-97C5-575095D491B1

P577

Q39828440-6D9CD506-541A-4951-AC85-764B4C184E34

P5875

Q39828440-D024DB18-6E30-4259-BF73-88B9CF78D517

P698

Q39828440-4DA68443-A9AB-4314-8962-7802F955D057

P921

Q39828440-6028F8B9-ACA2-492E-BD44-35934B60627A

P932

Q39828440-751F5582-DECE-4E3A-92F0-71CADC87996A

P356

P1433

Journal of Experimental Medicine

P1476

Blockade of CTLA-4 on both eff ...... ity of anti-CTLA-4 antibodies.

@en

P2093

Alan J Korman

http://www.w3.org/2001/XMLSchema#string

Cynthia A Chambers

http://www.w3.org/2001/XMLSchema#string

Karl S Peggs

http://www.w3.org/2001/XMLSchema#string

P2860

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Enhancement of antitumor immunity by CTLA-4 blockade

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells

CTLA-4 control over Foxp3+ regulatory T cell function

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

CTLA-4 regulates cell cycle progression during a primary immune response.

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

P304

1717-1725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20082492

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

206

http://www.w3.org/2001/XMLSchema#string

P50

Sergio A Quezada

James P. Allison

P577

2009-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26651222

http://www.w3.org/2001/XMLSchema#string

P698

19581407

http://www.w3.org/2001/XMLSchema#string

P921

P932

2722174

http://www.w3.org/2001/XMLSchema#string